Navigation Links
BMP Sunstone Receives SFDA Acceptance for Enablex(R) Clinical Trial
Date:5/6/2008

A Milestone Reached to Commercialize Leading OAB Drug in China

PLYMOUTH MEETING, Pa., May 6 /Xinhua-PRNewswire-FirstCall/ -- BMP Sunstone Corporation (Nasdaq: BJGP) ("BMP Sunstone" or the "Company") today announced that its Clinical Trial Application ("CTA") for Enablex(R) (Darifenacin) was officially accepted by China's State Food & Drug Administration ("SFDA"). CTA acceptance is a key SFDA requirement prior to pursuing a clinical trial and, ultimately, completing commercialization of a pharmaceutical product in China. The Company hopes to begin the clinical trial in the first half of 2009, and estimates that receipt of a market license could occur sometime in 2011.

Enablex(R) is a prescription medicine used in adults to treat symptoms of urinary incontinence, urgency and frequency related to an Overactive Bladder ("OAB"). Global annual sales of OAB medication are estimated to be USD$2.25 billion. In China, OAB afflicts an estimated 24-29% of the population over the age of 24, or over 200 million people. However, the treatment rates are historically low, with less than 15% of OAB sufferers in China seeking treatment.

"Today's announcement speaks to our unique ability to commercialize leading pharmaceutical products in the Chinese market," stated David Gao, Chief Executive Officer of BMP Sunstone. "CTA acceptance is one key step toward reaching marketability and we remain excited about the growth prospects for Enablex(R) in China. The addressable market for OAB medicines in China is a huge potentially opportunity and we believe we have the necessary resources to meet this developing market demand with Enablex(R)."

In November 2007, BMP Sunstone signed an exclusive agreement to register, market and distribute Enablex(R) in the People's Republic of China with Shanghai Novartis Trading Limited. Under the terms of the agreement, once approved, BMP Sunstone will have the exclusive rights to sell, market and distribute Enablex in China for ten years.

Gao continued, "Enablex(R) is a great example of our ability to target under-penetrated areas of China with drugs that improve the overall health of the population. We intend to continue to bring high value, niche-focused prescription drugs, with rigor and prudence, to the growing Chinese healthcare market."

About BMP Sunstone Corporation

BMP Sunstone Corporation is a specialty pharmaceutical company that is building a proprietary portfolio of branded pharmaceutical and healthcare products in China and is pursuing partnerships with other companies seeking to enter the Chinese pharmaceutical market. It is the only U.S. public company to offer industry partners a comprehensive suite of market-entry services in China that includes pre-market entry analysis, clinical trial management, product registration, market research, as well as pharmaceutical marketing and distribution. The company provides distribution services for a wide range of products, including Western medicines, traditional Chinese medicines, bio-chemical medicines, medical applications, branded generic pharmaceuticals, over-the-counter healthcare products, and home healthcare supplies and equipments. BMP Sunstone's proprietary portfolio, primarily focusing on women's health and pediatrics. The Company is headquartered in Plymouth Meeting, Pennsylvania.

About Shanghai Novartis Trading Co.

Shanghai Novartis Trading Co. is a wholly owned subsidiary of Novartis AG (NYSE: NVS).

Safe Harbor Statement

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical fact, including statements regarding commercialization and growth prospects of Enablex, the timing of clinical trials and receipt of a market license for Enablex, the addressable market for OAB medicine in China and whether the Company has the necessary resources to meet the market demand for Enablex. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, the non-acceptance by patients to accept a pharmaceutical treatment for OAB, the failure to obtain any necessary approvals to market Enablex(R) and other risks contained in reports filed by the Company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

For more information, please contact:

BMP Sunstone Corporation

Fred M. Powell

Chief Financial Officer

Tel: +1-610-940-1675

Integrated Corporate Relations, Inc.

Ashley Ammon MacFarlane and Christine Duan

Tel: +1-203-682-8200 (Investor Relations)


'/>"/>
SOURCE BMP Sunstone Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
5. IsoTis Receives FDA Clearance for Accell Family of Products
6. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
7. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
8. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
9. XTL Receives Staff Letter From NASDAQ
10. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
11. Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2016)... ... May 18, 2016 , ... Shimadzu Scientific ... The University of Toledo. This two-day camp will take place annually starting June ... field of pharmaceutical sciences in preparation for a university academic program. , ...
(Date:5/18/2016)... ... 18, 2016 , ... Every day, more than 5,400 ER ... Costing more than $56 billion in direct costs annually, asthma remains a critical ... the suffering associated with uncontrolled asthma can be overwhelmingly disproportionate and better managed,” ...
(Date:5/17/2016)... May 18, 2016 Haselmeier announces ... pen following approval by EMA, the European Medicines Agency. ... and technology company, the new pen version includes enhancements ... level of confidence to patients during use. ... pen easier to handle with a larger display window ...
(Date:5/17/2016)... ... 2016 , ... PATH and Laerdal Global Health announced today ... feeding cup to market based on a reference design co-developed by PATH, the ... Hospital, thereby ensuring an innovative feeding option for the 7.6 million preterm infants ...
Breaking Biology Technology:
(Date:5/20/2016)... 20, 2016  VoiceIt is excited to announce ... By working together, VoiceIt and VoicePass ... and VoicePass take slightly different approaches to voice ... security and usability. ... new partnership. "This marketing and technology ...
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
Breaking Biology News(10 mins):